Genfit Sa · EURONEXT:GNFT
Genfit Sa — Investor Presentation (February 2026)
28 slides from Genfit Sa's investor presentation, February 2026
Slide 1: Corporate Presentation
Corporate Presentation F e b r u ar y 2 0 26
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED B
Slide 3: Strategic Highlights and Value Drivers
Strategic Highlights and Value Drivers Iqirvo®: Strong commercial sales1 trajectory in PBC 1 • Key contributing factor to GENFIT ‘s robust financial position • Next update by IPSEN: February 12, 2026 G1090N in ACLF: Safety profile and anti-inflammatory activity 2 • A promising investigational candid
Slide 4: 1. Who we are
1.Who we are 2. R&D focus 3. Iqirvo® in PBC
Slide 5: Corporate Highlights
Corporate Highlights French biopharmaceutical company ACLF Continuum3 Listed on EURONEXT “GNFT” • Lead asset: G1090N • Other assets: SRT-015 | CLM-022 | VS-02-HE 25+ years in liver diseases, taking • EViv (Research collaboration) early assets to commercial stage1 CCA Our Focused on rare, severe live
Slide 6: Pipeline
Pipeline ► RESEARCH & DEVELOPMENT1 Preclinical Phase 1 Phase 2 Next expected/targeted steps2 G1090N3 Potential initiation of Phase 2 POCF SRT-0154 Potential initiation of FIHG targeted 2H26 ACLF CLM-0225 Potential initiation of FIHG targeted 1H27 Continuum* VS-02-HE Potential initiation of FIHG targ
Slide 7: Targeting Untapped Markets with High Potential
Targeting Untapped Markets with High Potential ACLF Oncology Prevalence of ACLF 294,000 in 2021, US, EU4, UK Prevalence of CCA ~$3.1Bn 20,000 to 30,000 for US, EU4, UK Market estimates for CCA ~300,000 by 2036 for US, EU4, UK Growing at Epidemic Rates +26% between 2006 and 2014 1 ~€160-200M Prevalen
Slide 8: 2. R&D focus
Acute-on-Chronic Liver Failure (ACLF) Life-threatening worsening of pre-existing advanced chronic liver disease covering a broad spectrum of conditions across a disease continuum including acute decompensation (AD) of liver cirrhosis and hepatic encephalopathy (HE) G1090N │ SRT-015 │ CLM-022 │ VS-02
Slide 9: ACLF: A High Unmet Need
ACLF: A High Unmet Need CHRONIC PHASE ACUTE PHASE Acute Chronic Liver Disease Cirrhosis ACLF 23-74% mortality at 28 days Decompensation = UNDERLYING CONDITION = PRECIPITANT ≥ 1 ORGAN DYSFUNCTIONS/FAILURES ► NO APPROVED DRUGS Bacterial Alcohol Alcohol Viruses Kidney Cerebral Infection Consumption Con
Slide 10: ACLF: R&D Programs
ACLF: R&D Programs We are developing a diversified pipeline based on pathophysiology Research Collaboration to better address the complexities of the condition and improve treatment outcomes with EVerZom1 G1090N SRT-015 CLM-022 VS-02-HE EViv Oral Injectable Oral Injectable Anti-inflammatory ASK1 NLR
Slide 11: Target Multiple Pathways
Target Multiple Pathways Acute Insult LIVER CIRRHOSIS/CLD • Immune-mediated tissue damage 1 • Mitochondrial dysfunction Liver Dysfunction 1 • Oxidative Stress • Dysbiosis Gut/Liver axis Portal • Bacterial Hypertension 1-2-3 5 translocation 4 • Cell Death • PAMPs Hyperammonemia • DAMPs 1-2-3 SYSTEMIC
Slide 12: A Strong Scientific Rationale for investigational drug G1090N, Our Lead Asset in ACLF
A Strong Scientific Rationale for investigational drug G1090N, Our Lead Asset in ACLF Findings to date: G1090N ✓ Decreases systemic inflammation in animal models, including in ACLF models ✓ Protects liver, kidney & brain in rat models of ACLF by decreasing tissue damage Anti-inflammatory Oral ✓ Prot
Slide 13: G1090N: Phase 1 Study Design
G1090N: Phase 1 Study Design CT.gov #: NCT07110441 A Phase 1 open-label study to assess pharmacokinetics, safety, and tolerability G1090N of G1090N in healthy subjects Anti-inflammatory Oral Key inclusion criteria Investigational drug G1090N is • Healthy Volunteers a promising therapy in ACLF NTOTAL
Slide 14: G1090N's Potential Recently Confirmed in the Clinic
G1090N’s Potential Recently Confirmed in the Clinic G1090N Anti-inflammatory Oral The safety profile observed in Phase 1 and the consistent biological activity evidenced in ex vivo assays represent a meaningful step in development. These findings position G1090N as a promising candidate for patients
Slide 15: SRT-015
SRT-015 Findings to date: SRT-015 ✓ Decreases systemic inflammation in animal models, including in an ACLF model ASK1 ✓ Protects mice from mortality in a model of sepsis induced by gut leakage inhibitor Injectable ✓ Demonstrates efficacy when injected in mice with acute liver failure (AASLD24 poster
Slide 16: CLM-022
CLM-022 Findings to date: CLM-022 ✓ Protects the liver in pre-clinical ALF models NLRP3 ✓ Protects mice from mortality induced by gut leakage-induced sepsis inflammasome ✓ Dose-dependently inhibits IL-1β secretion (AASLD 2024 poster) inhibitor ✓ Shows potent inhibition of priming and activation step
Slide 17: VS-02-HE
VS-02-HE About ▪ One of the most common complications of liver cirrhosis and ACLF Hepatic ▪ A central nervous system disorder representing a diverse spectrum of neurologic symptoms VS-02-HE ▪ Excess ammonia induces alteration of cell metabolism and can result in brain edema Encephalopathy Urease inh
Slide 18: EViv: A Research Collaboration with EVerZom
Eviv: A Research Collaboration with EVerZom EViv Exosome Technology Injectable 18 Press release
Slide 19: 2. R&D focus
Acute-On-Chronic Liver Failure (ACLF) G1090N │ SRT-015 │ CLM-022 │ VS-02-HE │ EViv Cholangiocarcinoma (CCA) Malignancy of bile ducts. Without treatment <20% of patients survive 5 years from diagnosis1. KRAS mutation is not addressed by current treatments. GNS561 1. Who we are Urea Cycle Disorders (U
Slide 20: CCA with KRAS mutation: A High Unmet Need
CCA with KRAS mutation: A High Unmet Need Rare and aggressive liver malignancy ~30% of patients with CCA harbor KRAS mutations4 that develops in the bile ducts • one of the most common genes that might be mutated or amplified resulting in the overactivation of some of these pathways5 • As the cancer
Slide 21: Rationale for Combining Anticancer Therapies and GNS561, an Autophagy Inhibitor
Rationale for Combining Anticancer Therapies and investigational drug GNS561, an Autophagy Inhibitor GNS561 PPT1 inhibitor in #1 Anticancer Therapies combination with a MEK inhibitor Oral #2 GNS561 Chemotherapeutic agents (Autophagy inhibitor) MAP Kinase pathway targeted therapies By entering the ly
Slide 22: GNS561: Phase 1b/2a Study Design
GNS561: Phase 1b/2a Study Design CT.gov #: NCT05874414 GNS561 A Phase 1b/2a open-label, multicenter study to evaluate safety, pharmacokinetics (PK), pharmacodynamics PPT1 inhibitor in (PD) and efficacy of GNS561 in combination with trametinib in advanced KRAS mutated CCA after failure of combination
Slide 23: Phase 1b: Highly Encouraging Early Data
Phase 1b: Highly Encouraging Early Data GNS561 PPT1 inhibitor in combination with a MEK inhibitor Oral Advanced KRAS-mutated cholangiocarcinoma remains a formidable clinical challenge, and the emerging activity seen in this initial study is encouraging. Because MEK inhibition alone has historically
Slide 24: Moving Forward
Moving Forward • Phase 1b dose escalation will continue as planned to confirm activity signal • 1Q2026 - New data from next patient cohorts expected • 1H2026 - Completion expected results will be used to establish recommended Phase 2 combination doses • 2H2026 – targeted Phase 2 initiation Beyond CC
Slide 25: 2. R&D focus
Acute-On-Chronic Liver Failure (ACLF) G1090N │ SRT-015 │ CLM-022 │ VS-02-HE Cholangiocarcinoma (CCA) GNS561 Urea Cycle Disorders (UCD) & Organic Acidemias (OA) Ultra-rare disease: 1,900 HAC2,3,4 per year in children in US+EU4+UK. 1. Who we are High mortality (75% at 5 years2). Survivors often have s
Slide 26: VS-01-HAC in UCD/OA
VS-01-HAC in UCD/OA Findings to date: VS-01-HAC ✓ Preclinical proof of concept: Potential bridging • VS-01 achieved robust ammonia clearance, ranging from 6.0 ± 2.8 mL/min on Day 1 to 9.5 ± 3.8 mL/min on Day 101,2,3,4 therapy or first-line in minipigs treatment Peritoneal ✓ Clinical proof of concept
Slide 27: 3. Iqirvo in PBC
1. Who we are 2. R&D focus 3.Iqirvo® in PBC
Slide 28: Solid Commercial Performance from Ipsen in PBC
Solid Commercial Performance from Ipsen in PBC 1. 2. Rapid regulatory approvals1 Successful commercial launch Iqirvo® sales (global, quarterly) since commercial launch2 $144.4M 2024 2025 $56.0M FDA 3 major EU $88.4M countries $39.7M Feb12 2026 Reimbursement $48.7M IPSEN 2025 EMA results $24.6M $24.1